These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 36598325)
41. Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase beta (RPTPbeta) to tenascin C. Adamsky K; Schilling J; Garwood J; Faissner A; Peles E Oncogene; 2001 Feb; 20(5):609-18. PubMed ID: 11313993 [TBL] [Abstract][Full Text] [Related]
42. Expression of cadherin and CSF dissemination in malignant astrocytic tumors. Asano K; Kubo O; Tajika Y; Takakura K; Suzuki S Neurosurg Rev; 2000 Mar; 23(1):39-44. PubMed ID: 10809486 [TBL] [Abstract][Full Text] [Related]
44. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Naumnik W; Nilklińska W; Ossolińska M; Chyczewska E Folia Histochem Cytobiol; 2009; 47(4):703-9. PubMed ID: 20430742 [TBL] [Abstract][Full Text] [Related]
45. Extracellular matrix of glioblastoma inhibits polarization and transmigration of T cells: the role of tenascin-C in immune suppression. Huang JY; Cheng YJ; Lin YP; Lin HC; Su CC; Juliano R; Yang BC J Immunol; 2010 Aug; 185(3):1450-9. PubMed ID: 20622113 [TBL] [Abstract][Full Text] [Related]
46. The effects of E-cadherin and bcl-2 on prognosis in patients with breast cancer. Kavgaci H; Yildiz B; Fidan E; Reis A; Ozdemir F; Cobanoglu U; Can G Bratisl Lek Listy; 2010; 111(9):493-7. PubMed ID: 21180263 [TBL] [Abstract][Full Text] [Related]
47. Tenascin-C as a prognostic determinant of colorectal cancer through induction of epithelial-to-mesenchymal transition and proliferation. Yang Z; Zhang C; Qi W; Cui C; Cui Y; Xuan Y Exp Mol Pathol; 2018 Oct; 105(2):216-222. PubMed ID: 30170017 [TBL] [Abstract][Full Text] [Related]
48. Soluble Neural-cadherin as a novel biomarker for malignant bone and soft tissue tumors. Niimi R; Matsumine A; Iino T; Nakazora S; Nakamura T; Uchida A; Sudo A BMC Cancer; 2013 Jun; 13():309. PubMed ID: 23799912 [TBL] [Abstract][Full Text] [Related]
49. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. De Santis R; Albertoni C; Petronzelli F; Campo S; D'Alessio V; Rosi A; Anastasi AM; Lindstedt R; Caroni N; Arseni B; Chiodi P; Verdoliva A; Cassani G; Chinol M; Paganelli G; Carminati P Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2191-6. PubMed ID: 16609034 [TBL] [Abstract][Full Text] [Related]
51. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Gazzaniga P; Gradilone A; Giuliani L; Gandini O; Silvestri I; Nofroni I; Saccani G; Frati L; Aglianò AM Ann Oncol; 2003 Jan; 14(1):85-90. PubMed ID: 12488298 [TBL] [Abstract][Full Text] [Related]
52. Tenascin-C: a novel candidate marker for cancer stem cells in glioblastoma identified by tissue microarrays. Nie S; Gurrea M; Zhu J; Thakolwiboon S; Heth JA; Muraszko KM; Fan X; Lubman DM J Proteome Res; 2015 Feb; 14(2):814-22. PubMed ID: 25469866 [TBL] [Abstract][Full Text] [Related]
53. Relationships between clinical behavior of laryngeal squamous cell carcinomas and expression of VEGF, MMP-9 and E-cadherin. Akdeniz O; Akduman D; Haksever M; Ozkarakas H; Müezzinoglu B Asian Pac J Cancer Prev; 2013; 14(9):5301-10. PubMed ID: 24175817 [TBL] [Abstract][Full Text] [Related]
54. Clinical significance of serum tenascin-C levels in breast cancer. Tastekin D; Tas F; Karabulut S; Duranyildiz D; Serilmez M; Guveli M; Vatansever S Tumour Biol; 2014 Jul; 35(7):6619-25. PubMed ID: 24696262 [TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma. Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kulesza-Bronczyk B; Kinalski M; Terlikowski SJ Tumour Biol; 2015 Jun; 36(6):4157-65. PubMed ID: 25577253 [TBL] [Abstract][Full Text] [Related]
56. Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting. Lingasamy P; Laarmann AH; Teesalu T Curr Cancer Drug Targets; 2021; 21(1):70-79. PubMed ID: 33001014 [TBL] [Abstract][Full Text] [Related]
58. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma. Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833 [TBL] [Abstract][Full Text] [Related]
59. Correlation of local and systemic expression of survivin with histopathological parameters of cutaneous melanoma. Jović M; Cerović S; Zolotarevska L; Gačević M; Stanojević I; Miller K; Đukić M; Saso L; Jauković L; Vojvodić D Vojnosanit Pregl; 2016 Nov; 73(11):1022-9. PubMed ID: 29328641 [TBL] [Abstract][Full Text] [Related]
60. High expression of survivin predicts poor prognosis in cervical squamous cell carcinoma treated with paclitaxel and carboplatin. Zhang Y; Yan H; Li R; Guo Y; Zheng R Medicine (Baltimore); 2019 May; 98(20):e15607. PubMed ID: 31096466 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]